Lyra Therapeutics (LYRA) Other Operating Expenses (2022 - 2025)

Lyra Therapeutics (LYRA) recorded quarterly Other Operating Expenses of -$31000.0 in Q4 2025, down 1450.0% on a QoQ basis from -$2000.0 in Q2 2025.

Lyra Therapeutics (LYRA) Other Operating Expenses (2022 - 2025) Analysis & Trends

Lyra Therapeutics (LYRA) has reported Other Operating Expenses for 4 consecutive years, with -$31000.0 the latest figure, recorded in Q4 2025.

Other Operating Expenses for Q4 2025 came in at -$31000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$48000.0 (down 100.19% YoY), and the FY2025 annual result was -$31000.0, down 100.13% from the prior year.
Other Operating Expenses for Q4 2025 stood at -$31000.0, down from -$2000.0 in the prior quarter.
The five-year high for Other Operating Expenses was $24.7 million in Q2 2024, with the low at -$31000.0 in Q4 2025.
A 4-year average of $4.6 million and a median of $657000.0 in 2022 frame the typical range for Other Operating Expenses.
Across the five-year window, Other Operating Expenses surged 1452.7% in 2024 and plunged 100.01% in 2025, its largest moves.
Lyra Therapeutics' Other Operating Expenses stood at $1.3 million in 2022, then rose by 20.97% to $1.6 million in 2023, then surged by 1452.7% to $24.7 million in 2024, then slumped by 100.13% to -$31000.0 in 2025.
The last three Other Operating Expenses figures came in at -$31000.0 (Q4 2025), -$2000.0 (Q2 2025), and -$15000.0 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lyra Therapeutics	70,995.28	70,995.28	-

Download Data